findmyKOL

Emmanuel Antonarakis, MD

Enriched profile

Clark Endowed Professor of Medicine; Director of Genitourinary Oncology, Division of Hematology, Oncology and Transplantation, Department of Medicine · University of Minnesota Medical School

ORCIDNPI
Region🇺🇸 Minneapolis, MN · Midwest · United StatesSpecialtyMedical OncologyFocusProstate Cancer Treatment and Research+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Emmanuel Antonarakis is Clark Endowed Professor of Medicine; Director of Genitourinary Oncology, Division of Hematology, Oncology and Transplantation, Department of Medicine at University of Minnesota Medical School. OpenAlex indexes 1,495 publications with 36,361 citations (h-index 83); ClinicalTrials.gov lists 8 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Emmanuel Antonarakis, M.D., is Clark Endowed Professor of Medicine at University of Minnesota Medical School (Masonic Cancer Center). The public record shows 1,495 publications with 36,361 citations (h-index 83), centered on Prostate Cancer Treatment and Research, Prostate Cancer Diagnosis and Treatment, Radiopharmaceutical Chemistry and Applications. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 23 companies.

  • Most recent indexed publication: 2026 · Clinical cancer research
  • Top research focus: Prostate Cancer Treatment and Research
  • 8 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 23 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Prostate Cancer8 trials

Research focus

OpenAlex concept fingerprint
Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentRadiopharmaceutical Chemistry and ApplicationsCancer, Lipids, and MetabolismCancer Immunotherapy and Biomarkers

Drugs & molecules

across trials, industry payments and publications
Xtandigeneric · EnzalutamideClinical trials2Industry payments3Publications17Xofigogeneric · RadiumClinical trials1Industry payments16Publications1Jevtanageneric · CabazitaxelClinical trials1Industry payments10Publications2

Works with

trial sponsors and companies reporting payments
Bayer HealthCare Pharmaceuticals Inc.Clinical trialsIndustry payments27Merck Sharp & Dohme LLCClinical trialsIndustry payments23Abbvie Inc.Clinical trialsIndustry payments11

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
1,495publications

Distinct works indexed by OpenAlex, matched via ORCID; 88 in PubMed.

36,361citations

Total citations across indexed works.

83h-index

Hirsch index (OpenAlex). i10-index 361.

Clinical & industry

trials, payments and federal funding
8clinical trials

Investigator role on registered studies.

View trials
23companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

23 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    48.9%
    Anti-androgens13.9%
    Nubeqa100%
    Part D<11 patients
    Cytochrome P450 17A1 Inhibitor12.5%
    Abiraterone Acetate100%
    Part D<11 patients
  • Metabolism & gastrointestinal

    28%
    Corticosteroid21.5%
    Prednisone100%
    Part D23 patients
    Serotonin-3 Receptor Antagonist6.6%
    Ondansetron Odt58%Ondansetron Hcl42%
    Part D<11 patients
  • Cardiovascular

    7.8%
    Statin5%
    Rosuvastatin Calcium52%Atorvastatin Calcium48%
    Part D<11 patients
    ACE inhibitor2.8%
    Lisinopril100%
    Part D<11 patients
4 more therapeutic areas behind the reveal.Reveal →
Where care is delivered (Part B)83.2% facility · 16.8% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Mario A. Eisenberger335Elisabeth I. Heath323Michael A. Carducci284

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/emmanuel-antonarakis-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • LinkedIn

    linkedin.com/in/emmanuel-s-antonarakis-m-d-854a4b13

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
  • X / Twitter

    x.com/EAntonarakis

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com

Mentions by others

where others cite or feature them
  • Other

    cancer.umn.edu/news/dr-emmanuel-antonarakis-named-masonic-cancer-center-associate-director-translational-research

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.umn.edu
  • Other

    cancer.umn.edu/staff/emmanuel-antonarakis

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.umn.edu
  • Other

    experts.umn.edu/en/persons/emmanuel-antonarakis

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →experts.umn.edu
2 more mentions behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • MD

    University of Wales College of Medicine, Cardiff, Wales, UK

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.umn.edu
  • Internship

    University Hospital of Wales, Cardiff, Wales, UK

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.umn.edu
  • Residency in Internal Medicine

    Johns Hopkins Bayview Medical Center, Baltimore, MD

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.umn.edu
  • Fellowship in Medical Oncology

    Johns Hopkins Hospital, Baltimore, MD

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.umn.edu
  • verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.umn.edu

Editorial & leadership roles

journal and society appointments
1 more role behind the reveal.Reveal →

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances
3 more media items behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.